Etanercept (Enbrel): update on therapeutic use

Area of Science:

• Rheumatology
• Immunology
• Pharmacology

Background:

• Tumour necrosis factor (TNF) is a key mediator in inflammatory articular diseases like rheumatoid arthritis (RA) and psoriatic arthritis (PsA).
• Etanercept (Enbrel) is an approved TNF inhibitor demonstrating efficacy in RA and juvenile RA (JRA).
• Long-term studies confirm etanercept's sustained control of RA and JRA signs and symptoms with a consistent safety profile.

Purpose of the Study:

• To evaluate etanercept as a first-line treatment for early active RA in methotrexate-naïve patients.
• To assess etanercept's impact on radiographic progression in early RA.
• To determine etanercept's efficacy in patients with severe psoriatic arthritis (PsA).

Main Methods:

• A double-blind, placebo-controlled study compared etanercept (25 mg twice weekly) with methotrexate (median 20 mg/week) in early active RA.
• A separate double-blind, placebo-controlled study investigated etanercept in severe PsA.
• Radiographic progression was assessed as a key outcome measure.

Main Results:

• Both etanercept and methotrexate effectively reduced signs and symptoms of RA.
• Etanercept demonstrated significantly greater efficacy than methotrexate in slowing the rate of radiographic erosions in RA.
• Etanercept proved effective in reducing disease activity in patients with severe PsA.

Conclusions:

• Etanercept is an effective first-line treatment option for early active RA, outperforming methotrexate in inhibiting radiographic progression.
• Etanercept also shows significant efficacy in managing severe psoriatic arthritis.
• Etanercept is well-tolerated and represents a valuable therapeutic option for inflammatory articular diseases.